Post Marketing Trial (Phase IV) on the Safety, Tolerability And Efficacy of Eribulin Mesylate in Treating Patients with Locally Advanced or Metastatic Breast Cancer
Phase of Trial: Phase IV
Latest Information Update: 09 Feb 2019
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 25 Sep 2018 Planned number of patients changed from 200 to 83.
- 25 Sep 2018 Planned End Date changed from 15 Sep 2019 to 1 Jun 2019.
- 25 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Feb 2019.